ES2633353T3 - Péptidos derivados de lactoferrina humana y su uso - Google Patents
Péptidos derivados de lactoferrina humana y su uso Download PDFInfo
- Publication number
- ES2633353T3 ES2633353T3 ES12701866.1T ES12701866T ES2633353T3 ES 2633353 T3 ES2633353 T3 ES 2633353T3 ES 12701866 T ES12701866 T ES 12701866T ES 2633353 T3 ES2633353 T3 ES 2633353T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- peptide
- peptides
- tnf
- peptides derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 77
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 21
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 title 1
- 102000050459 human LTF Human genes 0.000 title 1
- 210000004027 cell Anatomy 0.000 description 14
- 238000012216 screening Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000007621 bhi medium Substances 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152213 | 2011-01-26 | ||
| EP11152213A EP2481751A1 (en) | 2011-01-26 | 2011-01-26 | Human lactoferrin derived peptides |
| PCT/EP2012/051112 WO2012101157A1 (en) | 2011-01-26 | 2012-01-25 | Human lactoferrin derived peptides and there use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2633353T3 true ES2633353T3 (es) | 2017-09-20 |
Family
ID=44123487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12700715.1T Active ES2645959T3 (es) | 2011-01-26 | 2012-01-25 | Péptidos basados en lactoferrina humana que tienen actividad antiinflamatoria |
| ES12701866.1T Active ES2633353T3 (es) | 2011-01-26 | 2012-01-25 | Péptidos derivados de lactoferrina humana y su uso |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12700715.1T Active ES2645959T3 (es) | 2011-01-26 | 2012-01-25 | Péptidos basados en lactoferrina humana que tienen actividad antiinflamatoria |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8846608B2 (OSRAM) |
| EP (3) | EP2481751A1 (OSRAM) |
| JP (2) | JP6158712B2 (OSRAM) |
| KR (2) | KR101949210B1 (OSRAM) |
| CN (2) | CN103459419B (OSRAM) |
| AU (2) | AU2012210564B2 (OSRAM) |
| BR (2) | BR112013018264A2 (OSRAM) |
| CA (2) | CA2825247A1 (OSRAM) |
| ES (2) | ES2645959T3 (OSRAM) |
| MX (2) | MX342313B (OSRAM) |
| PL (1) | PL2668205T3 (OSRAM) |
| RU (2) | RU2596393C2 (OSRAM) |
| WO (2) | WO2012101157A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
| GB201401877D0 (en) * | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| CN104888202A (zh) * | 2014-05-22 | 2015-09-09 | 闫牧乔 | 一种治疗扁桃体炎的药物 |
| IT201800002457A1 (it) * | 2018-02-07 | 2019-08-07 | Neilos S R L | Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie |
| RU2681310C1 (ru) * | 2018-09-05 | 2019-03-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ первичной хирургической обработки инфицированных ран кожи и мягких тканей с использованием пептида Gly-His-Lys-D-Ala |
| RU2681216C1 (ru) * | 2018-09-05 | 2019-03-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ стимуляции регенерации инфицированных ран кожи и мягких тканей с применением пептида Gly-His-Lys-D-Ala |
| WO2020096672A1 (en) | 2018-11-09 | 2020-05-14 | The Wistar Institute Of Anatomy And Biology | Use of lactoferrin for generating myeloid-derived suppressor cells |
| KR102032945B1 (ko) * | 2018-12-03 | 2019-10-16 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
| NL2024839B1 (en) * | 2020-02-05 | 2021-09-13 | Cbmr Scient Nanoscience B V | Antimicrobial peptide for treatment and controlling skin disorders relating to microbial infection |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2818056B2 (ja) | 1990-09-07 | 1998-10-30 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
| EP0629347B1 (en) | 1992-01-23 | 1997-07-02 | Morinaga Milk Industry Co., Ltd. | Antibacterial agent and treatment of article therewith |
| JP3347819B2 (ja) | 1993-06-28 | 2002-11-20 | 森永乳業株式会社 | 抗菌性ペプチドの精製方法 |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JP3529423B2 (ja) | 1994-04-01 | 2004-05-24 | 森永乳業株式会社 | 抗菌性ペプチドの製造方法 |
| JP3812957B2 (ja) | 1994-08-02 | 2006-08-23 | 森永乳業株式会社 | 角膜損傷治療剤 |
| JPH08143468A (ja) | 1994-11-17 | 1996-06-04 | Morinaga Milk Ind Co Ltd | 抗潰瘍剤 |
| WO1998006425A1 (en) | 1996-08-12 | 1998-02-19 | A+ Science Invest Ab | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| SE9804614A0 (en) | 1998-07-06 | 2000-01-07 | A+ Science Invest Ab | New peptides and use thereof |
| US6399570B1 (en) | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| EP1202620A1 (en) * | 1999-05-14 | 2002-05-08 | The Regents of the University of California | Anti-inflammatory therapy for inflammatory mediated infection |
| CA2388910C (en) | 1999-11-11 | 2008-10-07 | Am-Pharma B.V. | Antimicrobial activity of the first cationic cluster of human lactoferrin |
| RU2165769C1 (ru) * | 2000-07-13 | 2001-04-27 | Якубовская Раиса Ивановна | Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения |
| SE0102067D0 (sv) | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| WO2006047744A2 (en) | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| EP2078529B1 (en) * | 2006-07-10 | 2014-12-10 | PBA3 Biomed GmbH | Antimicrobial peptides |
| WO2008096816A1 (ja) | 2007-02-09 | 2008-08-14 | Genomidea Inc. | 血管新生誘導剤及びそれに用いられるポリペプチド |
| WO2008096814A1 (ja) * | 2007-02-09 | 2008-08-14 | Genomidea Inc. | 新規ポリペプチド及びそれを有効成分として含有する抗菌剤 |
| EP2050461A1 (en) | 2007-10-19 | 2009-04-22 | PharmaSurgics in Sweden AB | Peptides based on the sequence of human lactoferrin and their use |
| EP2060586A1 (en) * | 2007-11-14 | 2009-05-20 | PharmaSurgics in Sweden AB | New synthetic arginine substituted peptides and their use |
| HUE028539T2 (en) * | 2008-05-23 | 2016-12-28 | Daiichi Sankyo Co Ltd | A peptide capable of extending the half-life of an important peptide in plasma |
| KR101406743B1 (ko) * | 2009-01-13 | 2014-06-20 | 페르가뭄 아베 | 상처, 흉터, 수술 후 유착 형성을 치료하기 위한 히알루론산 함유 조성물 |
| EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
| KR101341210B1 (ko) * | 2013-01-24 | 2013-12-12 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 신규한 항균 펩타이드 및 이의 용도 |
-
2011
- 2011-01-26 EP EP11152213A patent/EP2481751A1/en not_active Withdrawn
-
2012
- 2012-01-25 BR BR112013018264A patent/BR112013018264A2/pt not_active IP Right Cessation
- 2012-01-25 RU RU2013139294/10A patent/RU2596393C2/ru active
- 2012-01-25 JP JP2013550864A patent/JP6158712B2/ja not_active Expired - Fee Related
- 2012-01-25 PL PL12701866T patent/PL2668205T3/pl unknown
- 2012-01-25 BR BR112013018365A patent/BR112013018365A2/pt not_active IP Right Cessation
- 2012-01-25 ES ES12700715.1T patent/ES2645959T3/es active Active
- 2012-01-25 RU RU2013139302/04A patent/RU2593757C2/ru active
- 2012-01-25 CA CA2825247A patent/CA2825247A1/en not_active Abandoned
- 2012-01-25 EP EP12700715.1A patent/EP2668204B1/en not_active Not-in-force
- 2012-01-25 KR KR1020137021855A patent/KR101949210B1/ko not_active Expired - Fee Related
- 2012-01-25 EP EP12701866.1A patent/EP2668205B1/en not_active Not-in-force
- 2012-01-25 CN CN201280006526.XA patent/CN103459419B/zh not_active Expired - Fee Related
- 2012-01-25 US US13/981,614 patent/US8846608B2/en active Active
- 2012-01-25 ES ES12701866.1T patent/ES2633353T3/es active Active
- 2012-01-25 WO PCT/EP2012/051112 patent/WO2012101157A1/en not_active Ceased
- 2012-01-25 MX MX2013008530A patent/MX342313B/es active IP Right Grant
- 2012-01-25 CN CN201280006521.7A patent/CN103476792B/zh not_active Expired - Fee Related
- 2012-01-25 AU AU2012210564A patent/AU2012210564B2/en not_active Ceased
- 2012-01-25 US US13/981,609 patent/US9132165B2/en not_active Expired - Fee Related
- 2012-01-25 JP JP2013550865A patent/JP6158713B2/ja not_active Expired - Fee Related
- 2012-01-25 CA CA2825246A patent/CA2825246A1/en not_active Abandoned
- 2012-01-25 AU AU2012210565A patent/AU2012210565B2/en not_active Expired - Fee Related
- 2012-01-25 MX MX2013007995A patent/MX341020B/es active IP Right Grant
- 2012-01-25 WO PCT/EP2012/051111 patent/WO2012101156A2/en not_active Ceased
- 2012-01-25 KR KR1020137021856A patent/KR101933900B1/ko not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2633353T3 (es) | Péptidos derivados de lactoferrina humana y su uso | |
| Bai et al. | Bacterial biofilms and their implications in pathogenesis and food safety | |
| Xie et al. | Lactobacillus reuteri stimulates intestinal epithelial proliferation and induces differentiation into goblet cells in young chickens | |
| Wang et al. | In vitro evaluation of swine-derived Lactobacillus reuteri: probiotic properties and effects on intestinal porcine epithelial cells challenged with enterotoxigenic Escherichia coli K88 | |
| Sankaran-Walters et al. | Guardians of the gut: enteric defensins | |
| Cheng et al. | Actin‐based motility allows Listeria monocytogenes to avoid autophagy in the macrophage cytosol | |
| AR084536A1 (es) | Agentes antimicrobianos | |
| Thivierge et al. | Cathelicidin-like helminth defence molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan activities imply a specific adaptation to immune modulation | |
| Kemgang et al. | Fermented milk with probiotic Lactobacillus rhamnosus S1K3 (MTCC5957) protects mice from salmonella by enhancing immune and nonimmune protection mechanisms at intestinal mucosal level | |
| Shao et al. | The probiotic, Leuconostoc mesenteroides, inhibits Listeria monocytogenes biofilm formation | |
| Ren et al. | Immune evasion strategies of pathogens in macrophages: the potential for limiting pathogen transmission | |
| Choeisoongnern et al. | Potential probiotic Enterococcus faecium OV3-6 and its bioactive peptide as alternative bio-preservation | |
| Nayak et al. | Potential application of bacteriocins for sustainable aquaculture | |
| Bang et al. | Immunogenic properties of the human gut-associated archaeon Methanomassiliicoccus luminyensis and its susceptibility to antimicrobial peptides | |
| Yu et al. | Biosynthetic microcin J25 exerts strong antibacterial, anti-inflammatory activities, low cytotoxicity without increasing drug-resistance to bacteria target | |
| Baranska-Rybak et al. | Safety profile of antimicrobial peptides: camel, citropin, protegrin, temporin a and lipopeptide on HaCaT keratinocytes | |
| ES2955834T3 (es) | Variantes de plantaricina nc8alphabeta | |
| Farkas et al. | Effects of Lactobacillus plantarum 2142 and sodium n-butyrate in lipopolysaccharide-triggered inflammation: comparison of a porcine intestinal epithelial cell line and primary hepatocyte monocultures with a porcine enterohepatic co-culture system | |
| MX353230B (es) | Un bacteriofago para biocontrol de salmonella y en la preparacion o procesamiento de alimentos. | |
| CN113336827B (zh) | 一种低分子量抗菌肽yhx-2及其组合物和应用 | |
| RU2015105738A (ru) | Непатогенный штамм f18 е. coli и его применение | |
| Lim et al. | Efficacy of bacteriophage therapy on horizontal transmission of Salmonella Gallinarum on commercial layer chickens | |
| Ibarra-Martínez et al. | Antibacterial activity of supernatants of Lactoccocus lactis, Lactobacillus rhamnosus, Pediococcus pentosaceus and curcumin against Aeromonas hydrophila. In vitro study | |
| Kanthawong et al. | In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides | |
| Abramov et al. | Anti-Salmonella Defence and Intestinal Homeostatic Maintenance In Vitro of a Consortium Containing Limosilactobacillus fermentum 3872 and Ligilactobacillus salivariu s 7247 Strains in Human, Porcine, and Chicken Enterocytes |